SG47488A1 - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists - Google Patents

Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Info

Publication number
SG47488A1
SG47488A1 SG1996002238A SG1996002238A SG47488A1 SG 47488 A1 SG47488 A1 SG 47488A1 SG 1996002238 A SG1996002238 A SG 1996002238A SG 1996002238 A SG1996002238 A SG 1996002238A SG 47488 A1 SG47488 A1 SG 47488A1
Authority
SG
Singapore
Prior art keywords
pct
date jun
represents hydrogen
sec
formula
Prior art date
Application number
SG1996002238A
Other languages
English (en)
Inventor
Van Georges Henri Paul Daele
Jean-Paul Rene Marie A Bosmans
Van Willy Johannes C Laerhoven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG47488A1 publication Critical patent/SG47488A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG1996002238A 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists SG47488A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20

Publications (1)

Publication Number Publication Date
SG47488A1 true SG47488A1 (en) 1998-04-17

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002238A SG47488A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Country Status (31)

Country Link
US (2) US5674868A (es)
EP (1) EP0669919B1 (es)
JP (1) JP2830952B2 (es)
KR (1) KR0166661B1 (es)
AT (1) ATE176232T1 (es)
AU (1) AU680640B2 (es)
BG (1) BG62489B1 (es)
BR (1) BR9307477A (es)
CA (1) CA2149044C (es)
CZ (1) CZ287262B6 (es)
DE (1) DE69323322T2 (es)
DK (1) DK0669919T3 (es)
ES (1) ES2129615T3 (es)
FI (1) FI952458A (es)
GR (1) GR3029831T3 (es)
HU (2) HUT72740A (es)
IL (3) IL119273A (es)
LV (1) LV10956B (es)
MX (1) MX9307257A (es)
NO (2) NO307690B1 (es)
NZ (1) NZ257854A (es)
OA (1) OA10158A (es)
PL (1) PL176051B1 (es)
RO (1) RO115160B1 (es)
RU (1) RU2116072C1 (es)
SG (1) SG47488A1 (es)
SK (1) SK282378B6 (es)
TW (1) TW294595B (es)
UA (1) UA49792C2 (es)
WO (1) WO1994012494A1 (es)
ZA (1) ZA938676B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
WO1998047481A1 (en) 1997-04-18 1998-10-29 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
TR200000020T2 (tr) * 1997-07-11 2000-09-21 Janssen Pharmaceutica N.V. 5-HT3 ve 5-HT4 aracılı bozuklar için faydalı (+)-norsisaprit.
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2568835C (en) * 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
SI2271626T1 (sl) 2008-03-27 2015-03-31 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
US8168644B2 (en) 2008-03-27 2012-05-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
US5674868A (en) 1997-10-07
CZ287262B6 (en) 2000-10-11
SK282378B6 (sk) 2002-01-07
MX9307257A (es) 1994-05-31
AU680640B2 (en) 1997-08-07
PL309045A1 (en) 1995-09-18
BG99593A (en) 1995-12-29
NO307690B1 (no) 2000-05-15
NO951980L (no) 1995-05-19
ATE176232T1 (de) 1999-02-15
FI952458A0 (fi) 1995-05-19
FI952458A (fi) 1995-05-19
EP0669919A1 (en) 1995-09-06
IL119273A0 (en) 1996-12-05
BR9307477A (pt) 1999-06-29
OA10158A (en) 1996-12-18
NO995762L (no) 1995-05-19
AU5465994A (en) 1994-06-22
EP0669919B1 (en) 1999-01-27
LV10956B (en) 1996-10-20
ES2129615T3 (es) 1999-06-16
NO308530B1 (no) 2000-09-25
HU211546A9 (en) 1995-12-28
CA2149044C (en) 2007-04-03
RU2116072C1 (ru) 1998-07-27
LV10956A (lv) 1995-12-20
IL107654A0 (en) 1994-02-27
BG62489B1 (bg) 1999-12-30
NO951980D0 (no) 1995-05-19
TW294595B (es) 1997-01-01
DE69323322T2 (de) 1999-09-09
JPH08505840A (ja) 1996-06-25
HUT72740A (en) 1996-05-28
GR3029831T3 (en) 1999-06-30
CA2149044A1 (en) 1994-06-09
UA49792C2 (uk) 2002-10-15
DK0669919T3 (da) 1999-09-13
SK67595A3 (en) 1995-11-08
PL176051B1 (pl) 1999-03-31
RU95113434A (ru) 1997-03-10
NZ257854A (en) 1997-04-24
NO995762D0 (no) 1999-11-24
IL119273A (en) 2000-07-16
US5863923A (en) 1999-01-26
ZA938676B (en) 1995-05-19
RO115160B1 (ro) 1999-11-30
IL107654A (en) 1998-01-04
KR0166661B1 (ko) 1999-01-15
HU9501476D0 (en) 1995-07-28
WO1994012494A1 (en) 1994-06-09
DE69323322D1 (de) 1999-03-11
CZ125895A3 (en) 1995-10-18
JP2830952B2 (ja) 1998-12-02

Similar Documents

Publication Publication Date Title
HU9501476D0 (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists
HUT70154A (en) 5-ht4 receptor antagonists and pharmaceutical compositions containing them
GB9524157D0 (en) Therapeutic agents
SE0104332D0 (sv) Therapeutic agents
GB9121456D0 (en) Triazole antifungal agents
ZA931383B (en) Indoles
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
LTIP1960A (en) Positive inotropic and lusitropic pyrroloquinolinone derivatives, method for preparing thereof, pharmaceutical composition and method for preparing the same
LTIP1450A (en) Azaspiroalkane derivatives,processes for their preparation and pharmaceutical compositions containing them